Is the new Occlutech duct occluder an appropriate device for transcatheter closure of patent ductus arteriosus?

Godart, François; Houeijeh, Ali; Domanski, Olivia; Guillaume, Marie-Paule; Brard, Mélanie; Lucron, Hugues

doi:10.1016/j.ijcard.2018.03.059

Cited by 10 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this multicenter experience, the offlabel utilization of such devices appears effective in children and infants (median age: 1 year). The overall rate of successful AVP implantation (98.5%) constitutes a major indicator of efficacy which compares favourably with previous reports on use of AVPs and other devices formally developed for PDA or vascular occlusions [1][2][4][5][6][7][8][9][10][11][12][13][14]21,[25][26][27][28][29].…”

Section: Discussionsupporting

confidence: 76%

“…Continuous development of new techniques and material has made catheter treatment of congenital vascular malformation or congenital heart disease (CHD) possible in children and infants [1][2][3][4][5]. Percutaneous treatment has become the "gold standard" for the majority of patent ductus arteriosus (PDA) closures in children, including premature or low weight infants [1][2]5]. Several devices have been developed to occlude multiple vascular structures in adults, but the more recent ones such as the Amplatzer vascular plug (AVP) II and IV (Abbott Vascular®.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy, Safety and Characteristics of the Amplatzer Vascular Plug II and IV Utilization for Various Percutaneous Occlusions in Children under 10 Years

Lucron¹,

Baruteau²,

Ovaert³

et al. 2022

Congenital Heart Disease

Self Cite

View full text Add to dashboard Cite

Objectives: We aim to describe the efficacy, safety, and characteristics of the Amplatzer Vascular Plug (AVP) II and IV "off-label" use for multiple cardiovascular occlusions in children under 10 years. Methods: Observational retrospective multicenter (2007-2020, 6 centers) review of paediatric procedures using AVP II or IV. Results: A total of 125 children (49.6% aged ≤ 1 year, 147 lesions) underwent 136 successive procedures (success rate: 98.5%) using 169 devices (109 AVP IV, 60 AVP II). The mean device diameter was 7.7 ± 3.2 mm (4-20 mm). The median AVP size to vessel diameter ratio was 1.3 (0-2). The median age and weight at implantation were 1.0 year (0.01-9.98) and 8.4 kg (1-69). Procedures were heterogeneous (55 patent ductus arteriosus (PDA), 28 collaterals, 18 sequestrations, 22 arteriovenous/veinovenous/coronary fistulas, 6 vertical veins, 6 conduits, 5 ventricular septal defects, 7 miscellaneous). Day 1 and 6-month occlusion rates were respectively 94.8% and 98.5%. Major adverse events (MAE) occurred in 5.2% of cases (no procedure-related deaths), and more frequently in weight ≤ 5 kg (p = 0.01), younger patients (p = 0.03) during PDA closure (p = 0.02) of tubular types (p = 0.02) using larger devices (p = 0.03) and AVP II (p = 0.003). Independent predictor of MAE risk was a higher AVP diameter to patient weight ratio (Odds-ratio: 2.33, 95% confidence interval 1.31-4.13, p = 0.004, optimal cut off: 1.45). Conclusions: Both AVPs are safe and effective for percutaneous occlusions in children under 10. Such devices represent an alternative "off label" use for well selected paediatric patients.

show abstract

Section: Discussionsupporting

confidence: 76%

Section: Introductionmentioning

confidence: 99%

Efficacy, Safety and Characteristics of the Amplatzer Vascular Plug II and IV Utilization for Various Percutaneous Occlusions in Children under 10 Years

Lucron¹,

Baruteau²,

Ovaert³

et al. 2022

Congenital Heart Disease

Self Cite

View full text Add to dashboard Cite

show abstract

“…The ODO is a self-expanding device that, according to its manufacturers, is designed to close PDA of various morphologies and has been successfully implanted even in hypertensive PDA [2][3][4][7][8][9][10][11] , manufactured with nitinol wire coated with titanium oxide containing PTFE patch inside; marketed for approximately eight years by the Occlutech company whose factories are in Germany and Turkey, in our country the devices of Turkish origin are the ones that arrive 12 .…”

Section: Discussionmentioning

confidence: 99%

“…To date, the ideal device for the closure of patent ductus arteriosus (PDA) does not exist due to the diversity of its morphologies and sizes 1 . The Occlutech® Duct Occluder (ODO) is a relatively new device on which there are some experiences [2][3][4][5][6][7][8][9][10] . Our objective is to communicate the deformity that an ODO device presented when it was delivered transcatheter.…”

Section: Introductionmentioning

confidence: 99%

Deformidad en “forma de claxon” del dispositivo Occlutech-PDA: reporte de un caso

Ríos-Méndez¹,

Araúz-Martínez²

2022

Rev Fac Cien Med Univ Nac Cordoba

View full text Add to dashboard Cite

Introducción: existen comunicados sobre el fenómeno de la deformación de dispositivos oclusores de defectos intracardíacos durante el cateterismo, pero no acerca de los dispositivos oclusores para el conducto arterioso persistente. Objetivo: comunicar un caso de deformación de un relativamente nuevo tipo de dispositivo oclusor de conducto arterioso persistente. Método: se presenta un paciente adulto con conducto arterioso persistente hipertensivo y prueba de oclusión con balón positiva, en quien se intentó ocluirle con un dispositivo Occlutech®-PDA. Resultado: al momento de la entrega, el dispositivo adoptó la “forma de claxon” en lugar de “corcho de champagne” (apariencia habitual), motivo por el que fue retirado previo a su liberación y el procedimiento fue llevado a cabo con otro dispositivo. Conclusión: hasta donde conocemos, no hay comunicados acerca de deformación del dispositivo Occlutech®-PDA durante su implante mediante cateterismo. Los eventos adversos relacionados a nuevas tecnologías, como el presentado en este caso, deben ser comunicados tan pronto como sea posible, ya que esto puede ayudar a los fabricantes a mejorar su calidad y proveer mayor seguridad a los pacientes.

show abstract

“…The operation should even be stopped under deep hypothermia [6]. Therefore, open surgery of intracardiac malformations has gradually been replaced by interventional closure therapy for congenital heart disease [7, 8]. If congenital heart disease is combined with heart valvular disease and this requires hybrid procedure surgery, the VSD and PDA are blocked by transcatheter intervention before surgery.…”

Section: Discussionmentioning

confidence: 99%

Hybrid procedure for treating adult congenital heart disease with valvular heart disease in two patients

Liu

Zhong

Song

et al. 2019

J Cardiothorac Surg

View full text Add to dashboard Cite

BackgroundThe traditional approach for adult congenital heart disease combined with valvular disease is surgical treatment under cardiopulmonary bypass (CPB). This approach has a high incidence of postoperative complications, especially in patients with pulmonary hypertension and old age. We present two patients in whom the hybrid procedure was used to treat congenital malformations, followed by valve formation and replacement surgery.Case presentationA 63-year-old man had a muscular ventricular septal defect complicated by mitral regurgitation and a 57-year-old man had patent ductus arteriosus complicated by aortic stenosis. In both of the patients, the congenital malformation was successfully treated by the hybrid procedure, followed by valve repair or replacement. Both patients had no complications. A post-procedure echocardiogram showed no residual shunt across the duct.ConclusionsOur findings suggest that the hybrid procedure is a useful alternative for treating adult congenital heart disease with valvular heart disease. This procedure reduces the surgical incision and difficulty of surgery, shortens the CPB time, avoids residual leakage after surgery, and reduces recovery and hospitalization times.

show abstract

Is the new Occlutech duct occluder an appropriate device for transcatheter closure of patent ductus arteriosus?

Cited by 10 publications

References 18 publications

Efficacy, Safety and Characteristics of the Amplatzer Vascular Plug II and IV Utilization for Various Percutaneous Occlusions in Children under 10 Years

Efficacy, Safety and Characteristics of the Amplatzer Vascular Plug II and IV Utilization for Various Percutaneous Occlusions in Children under 10 Years

Deformidad en “forma de claxon” del dispositivo Occlutech-PDA: reporte de un caso

Hybrid procedure for treating adult congenital heart disease with valvular heart disease in two patients

Contact Info

Product

Resources

About